1. Gurpide E. Endometrial cancer: biochemical and clinical correlates. J Natl Cancer Inst 1991;83:405-16.
2. Christopherson WM, Alberhasky RC, Connelly PJ. Carcinoma of the endometrium: I. A clinicopathologic study of clear-cell carcinoma and secretory carcinoma. Cancer 1982;49:1511-23.
3. Lauchlan SC. Tubal (serous) carcinoma of the endometrium. Arch Pathol Lab Med 1981;105:615-8.
4. Lauchlan SC. The secondary mullerian system revisited. Int J Gynecol Pathol 1994;13:73-9.
5. Fanning J, Evans MC, Peters AJ, Samuel M, Harmon ER, Bates JS. Endometrial adenocarcinoma histologic subtypes: clinical and pathologic profile. Gynecol Oncol 1989;32:288-91.
6. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982;6:93-108.
7. Walker AN, Mills SE. Serous papillary carcinoma of the endometrium. A clinicopathologic study of 11 cases. Diagn Gynecol Obstet 1982;4:261-7.
8. Frumovitz M, Slomovitz BM, Singh DK, Broaddus RR, Abrams J, Sun CC, et al. Frozen section analyses as predictors of lymphatic spread in patients with early-stage uterine cancer. J Am Coll Surg 2004;199:388-93.
9. Kietlinska Z, Stelmachow J, Antczak A, Timorek A, Sawicki W, Tyminska B. [Preoperative evaluation of cervical involvement in endometrial cancer]. Ginekol Pol 1998;69:247-51.
10. Leminen A, Forss M, Lehtovirta P. Endometrial adenocarcinoma with clinical evidence of cervical involvement: accuracy of diagnostic procedures, clinical course, and prognostic factors. Acta Obstet Gynecol Scand 1995;74:61-6.
11. Mannel RS, Berman ML, Walker JL, Manetta A, DiSaia PJ. Management of endometrial cancer with suspected cervical involvement. Obstet Gynecol 1990;75:1016-22.
12. Morimura Y, Soeda S, Hashimoto T, Takano Y, Ohwada M, Yamada H, et al. The value of pre-operative diagnostic procedures for cervical involvement in uterine corpus carcinoma. Fukushima J Med Sci 2000;46:1-11.
13. Pete I, Godeny M, Toth E, Rado J, Pete B, Pulay T. Prediction of cervical infiltration in Stage II endometrial cancer by different preoperative evaluation techniques (D&C, US, CT, MRI). Eur J Gynaecol Oncol 2003;24:517-22.
14. Rubin SC, Hoskins WJ, Saigo PE, Nori D, Mychalczak B, Chapman D, et al. Management of endometrial adenocarcinoma with cervical involvement. Gynecol Oncol 1992;45:294-8.
15. Niloff JM, Klug TL, Schaetzl E, Zurawski VR Jr, Knapp RC, Bast RC, Jr. Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol 1984;148:1057-8.
16. Duk JM, Aalders JG, Fleuren GJ, de Bruijn HW. CA 125: a useful marker in endometrial carcinoma. Am J Obstet Gynecol 1986;155:1097-102.
17. Jhang H, Chuang L, Visintainer P, Ramaswamy G. CA 125 levels in the preoperative assessment of advanced-stage uterine cancer. Am J Obstet Gynecol 2003;188:1195-7.
18. Powell JL, Hill KA, Shiro BC, Diehl SJ, Gajewski WH. Preoperative serum CA-125 levels in treating endometrial cancer. J Reprod Med 2005;50:585-90.
19. Soper JT, Hunter VJ, Daly L, Tanner M, Creasman WT, Bast RC Jr. Preoperative serum tumor-associated antigen levels in women with pelvic masses. Obstet Gynecol 1990;75:249-54.
20. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009;105:103-4.
21. Kietlinska Z, Stelmachow J, Antczak-Judycka A, Timorek A, Sawicki W, Tyminska B. Fractional curettage, hysteroscopy and imaging techniques: transvaginal sonography (TVS), magnetic resonance imaging (MRI) and computed tomography (CT) in the diagnosis of cervical canal involvement in cases of endometrial carcinoma. Eur J Gynaecol Oncol 1998;19:561-4.
22. Lampe B, Kurzl R, Dimpfl T, Fawzi H. Accuracy of preoperative histology and macroscopic assessment of cervical involvement in endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol 1997;74:205-9.
23. Toki T, Oka K, Nakayama K, Oguchi O, Fujii S. A comparative study of pre-operative procedures to assess cervical invasion by endometrial carcinoma. Br J Obstet Gynaecol 1998;105:512-6.
24. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68:1331-7.
25. Alberico S, Facca MC, Millo R, Radillo L, Mandruzzato GP. Tumoral markers (CA 125--CEA) in the screening of ovarian cancer. Eur J Gynaecol Oncol 1988;9:485-9.
26. Jacobs I, Davies AP, Bridges J, Stabile I, Fay T, Lower A, et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ 1993;306:1030-4.
27. Skates SJ, Singer DE. Quantifying the potential benefit of CA 125 screening for ovarian cancer. J Clin Epidemiol 1991;44:365-80.
28. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990;97:922-9.
29. Mogensen O, Mogensen B, Jakobsen A, Sell A. Preoperative measurement of cancer antigen 125 (CA 125) in the differential diagnosis of ovarian tumors. Acta oncol 1989;28:471-3.
30. Zurawski VR Jr, Orjaseter H, Andersen A, Jellum E. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int J Cancer 1988;42:677-80.
31. Niloff JM, Knapp RC, Lavin PT, Malkasian GD, Berek JS, Mortel R, et al. The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer. Am J Obstet Gynecol 1986;155:56-60.
32. Santillan A, Garg R, Zahurak ML, Gardner GJ, Giuntoli RL 2nd, Armstrong DK, et al. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol 2005;23:9338-43.
33. Schilthuis MS, Aalders JG, Bouma J, Kooi H, Fleuren GJ, Willemse PH, et al. Serum CA 125 levels in epithelial ovarian cancer: relation with findings at second-look operations and their role in the detection of tumour recurrence. Br J Obstet Gynaecol 1987;94:202-7.
34. van der Burg ME, Lammes FB, Verweij J. The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer. Ann Oncol 1990;1:301-2.
35. Chung HH, Kim JW, Park NH, Song YS, Kang SB, Lee HP. Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer. Acta Obstet Gynecol Scand 2006;85:1501-5.
36. Dotters DJ. Preoperative CA 125 in endometrial cancer: is it useful? Am J Obstet Gynecol 2000;182:1328-34.
37. Hsieh CH, ChangChien CC, Lin H, Huang EY, Huang CC, Lan KC, et al. Can a preoperative CA 125 level be a criterion for full pelvic lymphadenectomy in surgical staging of endometrial cancer? Gynecol Oncol 2002;86:28-33.
38. Santala M, Talvensaari-Mattila A, Kauppila A. Peritoneal cytology and preoperative serum CA 125 level are important prognostic indicators of overall survival in advanced endometrial cancer. Anticancer Res 2003;23:3097-103.
39. Sood AK, Buller RE, Burger RA, Dawson JD, Sorosky JI, Berman M. Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome. Obstet Gynecol 1997;90:441-7.
40. Buza N, English DP, Santin AD, Hui P. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. Mod pathol 2013;26:1605-12.